« Back
Home /
Anti-Human DR5 (CT) - 0.1 mg

Anti-Human DR5 (CT) - 0.1 mg

Item no.	LEIN-D251-0.1mg
Manufacturer	Leinco Technologies
Amount	0.1 mg
Quantity options	0.1 mg 20 ug
Category	Antibodies Immunohistochemistry Western Blot Immunocytochemistry Primary Antibodies Immunochemistry
Type	Antibody Primary
Applications	WB, IHC, ICC
Specific against	Human (Homo sapiens)
Host	Rabbit
Citations	1. Pan, G. et al. (1997) Science 277:815-8 2. Sheridan, JP. et al. (1997) Science 277:818-21 3. Walczak, H. et al. (1997) EMBO J 16:5386-97 4. MacFarlane, M. et al. (1997) J Biol Chem 272:25417-20
ECLASS 10.1	32160702
ECLASS 11.0	32160702
UNSPSC	12352203
Shipping Condition	Room temperature
Available
Manufacturer - Applications	ICC, IHC FFPE, WB
Manufacturer - Category	Primary Monoclonal Antibodies>Apoptosis & Cell Biology
Manufacturer - Targets	DR5
Country of Origin	USA
Shipping Temperature	Next Day Ambient
Storage Conditions	This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Product Description	Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TRAIL/Apo2L is a new member of the TNF family. DR4 was recently identified as the receptor for TRAIL. A novel death domain containing receptor for TRAIL was more recently identified and designated DR5, Apo2, TRAIL-R2, TRICK2, or KILLER by several groups independently.1-4 Like DR4, DR5 transcript is widely expressed in normal tissues and in many types of tumor cells. DR5 binds to TRAIL and mediates TRAIL induced cell death. Overexpression of DR5 induces apoptosis and activates NF-κB.
Background	Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TRAIL/Apo2L is a new member of the TNF family. DR4 was recently identified as the receptor for TRAIL. A novel death domain containing receptor for TRAIL was more recently identified and designated DR5, Apo2, TRAIL-R2, TRICK2, or KILLER by several groups independently.^1-4 Like DR4, DR5 transcript is widely expressed in normal tissues and in many types of tumor cells. DR5 binds to TRAIL and mediates TRAIL induced cell death. Overexpression of DR5 induces apoptosis and activates NF-κB.
PubMed	DR5
Manufacturer - Specificity	Rabbit Anti-Human DR5 recognizes an epitope near the C-terminus of mouse and human DR5. This polyclonal antibody was purified using affinity chromatography.
RRID	AB_2829905
Concentration	0.5 mg/ml
Formulation	This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen	PN:D279
Additional Information	Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Keywords	Polyclonal Antibody, DR5, Apo2, TRAIL-R2, TRICK2, KILLER, Human TRAIL, Anti-Human DR5 (CT), DR5 Antibody, DR5, CD262, KILLER, TRICK2, TRICKB, ZTNFR9, TRAILR2, TRICK2A, TRICK2B, TRAIL-R2, KILLER/DR5, DR5, UNQ160/PRO186, Tumor necrosis factor receptor superfamily member 10B, Death receptor 5, TRAIL receptor 2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

LEIN-D251-0.1mg-safety-datasheet.pdf